Industry Conference

Highspot's new ChatGPT integration aims to solve AI's context problem in sales, embedding real-time deal data and content directly into the chat interface.

As AI demos flood Automate 2026, Datanomix stands out by proving its AI is already working, democratizing advanced analytics for manufacturers of all sizes.

A Berkeley startup is turning old clothes into virgin-quality materials using AI-designed enzymes. This isn't just recycling; it's a new economic model.

Behind every 5G signal and autonomous car are microscopic parts. At IMS 2026, KYOCERA AVX is revealing why these unseen components are the real investment story.

The promotion of Tony Pallas to CTO is no mere shuffle. It's a calculated move to arm thousands of franchisees with AI, signaling a new front in the war for hospitality tech dominance.

As return-to-office mandates clash with the needs of 5 million Canadians with migraine, the economic toll of inaction is mounting for employers.

A Canadian upstart is poised to unlock a massive, untreated market by moving glaucoma surgery from the OR to the office. This isn't just a new device; it's a strategic dismantling of a decades-old bottleneck.

Altera's Agilex 9 FPGA packs RF, compute, and memory into one chip, promising a leap in performance for defense, aerospace, and next-gen communications.

Septerna's novel oral drug for hypoparathyroidism could end the tyranny of injections and supplements, but its success hinges on a bigger bet: a new system for drugging life's most difficult molecular targets.

A new alliance between tech firm Seequent and think tank Cascade Institute aims to map Canada's vast, untapped geothermal reserves using novel AI.

New research shows 'Food is Medicine' programs thrive when paired with human coaching, offering a potent, scalable model for tackling chronic disease.

A new documentary on a Silicon Valley engineer turned cricket hero reveals a calculated strategy: to win America's heart, you must first tell its stories.

As National Outlet Shopping Day returns, it's more than a sale. It's Simon's blueprint for the future of retail and a key test of consumer spending.

With 80% of trials delayed, the life sciences industry is gathering to tackle its patient enrollment crisis. Can new partnerships and AI finally move the needle?

Promising early data for obesity drug DA-1726 shows rapid weight loss, while vanoglipel demonstrates powerful synergy in MASH and diabetes combination therapies.

With healthcare drowning in a $1 trillion administrative burden, CAQH's rebrand to DataSpring is more than a name change—it's a high-stakes bet.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

New trial data shows Sequel Med Tech's twiist™ AID system could bring much-needed simplicity and safety to millions with insulin-treated type 2 diabetes.